Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models
- 765 Downloads
Background and aims
Acute-on-chronic liver failure (ACLF) is a progressive disease associated with rapid clinical worsening and high mortality. Early prediction of mortality and intervention can improve patient outcomes. We aimed to develop a dynamic prognostic model and compare it with the existing models.
A total of 1402 ACLF patients, enrolled in the APASL-ACLF Research Consortium (AARC) with 90-day follow-up, were analyzed. An ACLF score was developed in a derivation cohort (n = 480) and was validated (n = 922).
The overall survival of ACLF patients at 28 days was 51.7%, with a median of 26.3 days. Five baseline variables, total bilirubin, creatinine, serum lactate, INR and hepatic encephalopathy, were found to be independent predictors of mortality, with AUROC in derivation and validation cohorts being 0.80 and 0.78, respectively. AARC-ACLF score (range 5–15) was found to be superior to MELD and CLIF SOFA scores in predicting mortality with an AUROC of 0.80. The point scores were categorized into grades of liver failure (Gr I: 5–7; II: 8–10; and III: 11–15 points) with 28-day cumulative mortalities of 12.7, 44.5 and 85.9%, respectively. The mortality risk could be dynamically calculated as, with each unit increase in AARC-ACLF score above 10, the risk increased by 20%. A score of ≥11 at baseline or persisting in the first week was often seen among nonsurvivors (p = 0.001).
The AARC-ACLF score is easy to use, dynamic and reliable, and superior to the existing prediction models. It can reliably predict the need for interventions, such as liver transplant, within the first week.
KeywordsCirrhosis ACLF AARC score Organ failure Liver failure
APASL ACLF research consortium
Acute-on-chronic liver failure
Hepatitis A virus
Hepatitis E virus
Hepatitis B virus
Severe alcoholic hepatitis
Trans-jugular liver biopsy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Approval of the institutional ethics committees was obtained.
Informed consent was taken from the patient or the next of kin.
- 2.Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, For CANONIC Study Investigators of the EASL–CLIF Consortium, et al. Acute on chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–1437CrossRefPubMedGoogle Scholar
- 4.Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, For CANONIC study investigators of the EASL-CLIF Consortium, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014;61(5):1038–1047CrossRefPubMedGoogle Scholar
- 8.Wang ZX, Yan LN, Wang WT, Xu MQ, Yang JY. Impact of pretransplant MELD score on post transplant outcome in orthotropic liver transplantation for patients with acute-on-chronic hepatitis B liver failure. Transplant Proc 2007;39:15011504Google Scholar
- 9.Jalan R, Pavesi M, Saliba F, Amorós A, Fernandez J, Holland-Fischer P, For CANONIC Study Investigators; EASL-CLIF Consortium, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol 2015;62(4):831–840CrossRefPubMedGoogle Scholar
- 11.Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós À, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Ginés P, Bernardi M, Arroyo V, CANONIC Study Investigators of EASL-CLIF Consortium. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol. 2014;60(2):275–281CrossRefPubMedGoogle Scholar